title: The influence of transdermal nicotine on tobacco/nicotine abstinence and the effects of a concurrently administered cigarette in women and men.
abstract: Transdermal nicotine (TN) is an efficacious smoking cessation pharmacotherapy thought to work, in part, by attenuating the effects of tobacco/nicotine abstinence and the effects of concurrently smoked cigarettes. Clinical trials suggest that TN may be less efficacious for women. This study explored the possibility of TN-related gender differences in > or = 8 hour abstinent smokers (54 women, 70 men) who completed four within-subject, double-blind, placebo-controlled sessions corresponding to 0, 7, 14, and 21 mg TN. In each approximately 6.5-hr long session participants smoked an own-brand cigarette 4 hours after TN administration and physiological and subjective outcomes were examined throughout each session. Results revealed that TN suppressed some signs and symptoms of tobacco abstinence and attenuated some effects of smoking, and these effects were not dependent on gender. Women were more sensitive to the direct effects of nicotine (e.g., ratings of Nauseous) and, independent of TN dose, self-administered less nicotine when smoking and rated smoking as less rewarding. Thus, although this study does not shed light on clinical observations that TN is less effective for women, results suggest that TN might need to be combined with other interventions to supplement its effects on tobacco/nicotine abstinence and concurrent smoking.
authors.affiliation: Department of Psychology, Virginia Commonwealth University, Richmond, VA 23298-0205, USA.
authors.forename: Bethea A
authors.initials: BA
authors.lastname: Kleykamp
authors.forename: Janine M
authors.initials: JM
authors.lastname: Jennings
authors.forename: Cynthia
authors.initials: C
authors.lastname: Sams
authors.forename: Michael F
authors.initials: MF
authors.lastname: Weaver
authors.forename: Thomas
authors.initials: T
authors.lastname: Eissenberg
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000704:Analysis of Variance; D016022:Case-Control Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008597:Menstrual Cycle; D009538:Nicotine / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D018722:Nicotinic Agonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D012727:Sex Characteristics; D012907:Smoking / Q000523:psychology*; D020340:Tobacco Use Cessation; D014029:Tobacco Use Disorder / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology
chemical_list: D018722:Nicotinic Agonists; D009538:Nicotine